Tubulin-binding dibenz[c,e]oxepinesCitation formats

Standard

Tubulin-binding dibenz[c,e]oxepines : Part 2. Structural variation and biological evaluation as tumour vasculature disrupting agents. / Rossington, Steven; Hadfield, J.; Shnyder, Steven D. et al.

In: Bioorganic and Medicinal Chemistry, Vol. 25, No. 5, 01.03.2017, p. 1630-1642.

Research output: Contribution to journalArticlepeer-review

Harvard

APA

Vancouver

Author

Rossington, Steven ; Hadfield, J. ; Shnyder, Steven D. et al. / Tubulin-binding dibenz[c,e]oxepines : Part 2. Structural variation and biological evaluation as tumour vasculature disrupting agents. In: Bioorganic and Medicinal Chemistry. 2017 ; Vol. 25, No. 5. pp. 1630-1642.

Bibtex

@article{10b26caed0964cc39f8262516c4c4b47,
title = "Tubulin-binding dibenz[c,e]oxepines: Part 2. Structural variation and biological evaluation as tumour vasculature disrupting agents",
abstract = "5,7-Dihydro-3,9,10,11-tetramethoxybenz[c,e]oxepin-4-ol 1, prepared from a dibenzyl ether precursor via Pd-catalysed intramolecular direct arylation, possesses broad-spectrum in vitro cytotoxicity towards various tumour cell lines, and induces vascular shutdown, necrosis and growth delay in tumour xenografts in mice at sub-toxic doses. The biological properties of 1 and related compounds can be attributed to their ability to inhibit microtubule assembly at the micromolar level, by binding reversibly to the same site of the tubulin αβ-heterodimer as colchicine 2 and the allocolchinol, N-acetylcolchinol 4.",
keywords = "Journal Article, tubulin, Tumour vasculature, direct arylation, palladium catalyst, Colchicine",
author = "Steven Rossington and J. Hadfield and Shnyder, {Steven D.} and Timothy Wallace and Kaye Williams",
note = "Copyright {\textcopyright} 2017 Elsevier Ltd. All rights reserved.",
year = "2017",
month = mar,
day = "1",
doi = "10.1016/j.bmc.2017.01.027",
language = "English",
volume = "25",
pages = "1630--1642",
journal = "Bioorganic & Medicinal Chemistry",
issn = "0968-0896",
publisher = "Elsevier BV",
number = "5",

}

RIS

TY - JOUR

T1 - Tubulin-binding dibenz[c,e]oxepines

T2 - Part 2. Structural variation and biological evaluation as tumour vasculature disrupting agents

AU - Rossington, Steven

AU - Hadfield, J.

AU - Shnyder, Steven D.

AU - Wallace, Timothy

AU - Williams, Kaye

N1 - Copyright © 2017 Elsevier Ltd. All rights reserved.

PY - 2017/3/1

Y1 - 2017/3/1

N2 - 5,7-Dihydro-3,9,10,11-tetramethoxybenz[c,e]oxepin-4-ol 1, prepared from a dibenzyl ether precursor via Pd-catalysed intramolecular direct arylation, possesses broad-spectrum in vitro cytotoxicity towards various tumour cell lines, and induces vascular shutdown, necrosis and growth delay in tumour xenografts in mice at sub-toxic doses. The biological properties of 1 and related compounds can be attributed to their ability to inhibit microtubule assembly at the micromolar level, by binding reversibly to the same site of the tubulin αβ-heterodimer as colchicine 2 and the allocolchinol, N-acetylcolchinol 4.

AB - 5,7-Dihydro-3,9,10,11-tetramethoxybenz[c,e]oxepin-4-ol 1, prepared from a dibenzyl ether precursor via Pd-catalysed intramolecular direct arylation, possesses broad-spectrum in vitro cytotoxicity towards various tumour cell lines, and induces vascular shutdown, necrosis and growth delay in tumour xenografts in mice at sub-toxic doses. The biological properties of 1 and related compounds can be attributed to their ability to inhibit microtubule assembly at the micromolar level, by binding reversibly to the same site of the tubulin αβ-heterodimer as colchicine 2 and the allocolchinol, N-acetylcolchinol 4.

KW - Journal Article

KW - tubulin

KW - Tumour vasculature

KW - direct arylation

KW - palladium catalyst

KW - Colchicine

U2 - 10.1016/j.bmc.2017.01.027

DO - 10.1016/j.bmc.2017.01.027

M3 - Article

C2 - 28143677

VL - 25

SP - 1630

EP - 1642

JO - Bioorganic & Medicinal Chemistry

JF - Bioorganic & Medicinal Chemistry

SN - 0968-0896

IS - 5

ER -